On July 13, 2026, Alto Neuroscience entered into an underwriting agreement to sell 3,776,436 shares at $26.48 per share, raising approximately $93.9 million. The proceeds will fund a Phase 3 trial for ALTO-207 in treatment-resistant depression and general working capital.

View Full Filing (SEC EDGAR)

2026-07-13

Alto Neuroscience (ANRO) filed a Form 8-K on July 13, 2026, covering Items 2.02 and 8.01. The filing discloses the company's cash, cash equivalents, and restricted cash as of June 30, 2026, under Item 8.01. This information is furnished but not filed for SEC purposes. The excerpt does not contain any specific financial numbers or results.

View Full Filing (SEC EDGAR)

View all Form 8-K filings

FAQ

Who are the top institutional investors holding ALTO NEUROSCIENCE INC (ANRO)?

Major stakeholders currently include Alpha Wave Global, LP ($83.4M), Commodore Capital LP ($61.2M), Vestal Point Capital, LP ($46.4M). Based on the latest 13F filings, there are a total of 110 tracked investment funds and institutions maintaining positions in ANRO.

What is the overall institutional sentiment toward ANRO recently?

Institutional sentiment appears Bullish (Net Buying). During the most recent reporting quarter, the stock experienced a net inflow of $170.0M, driven by 50 managers accumulating shares while 53 reduced their exposure.

Which institutions have been selling or reducing their ANRO positions?

In the latest period, 43 funds trimmed their holdings, and 10 managers completely exited their positions. The aggregate reported sell value was $175.9M.

Are there any notable investors adding ANRO to their portfolios?

Yes, buying activity remains notable. 21 institutions opened new positions in {ticker}, and 29 existing holders added to their shares. The total reported buy value for the quarter amounted to $299.9M.